These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
103 related articles for article (PubMed ID: 2906797)
1. Effect of ergolines on neurotransmitter systems in the rat brain. Moretti A; Carfagna N; Caccia C; Carpentieri M Arch Int Pharmacodyn Ther; 1988; 294():33-45. PubMed ID: 2906797 [TBL] [Abstract][Full Text] [Related]
2. Substituted ergolines: potential antipsychotics with unique profile. II. Neurochemical characterization. Auth F; Kiss B; Laszlovszky I; Lapis E Pol J Pharmacol Pharm; 1988; 40(6):603-11. PubMed ID: 2479935 [TBL] [Abstract][Full Text] [Related]
3. Pharmacological effects of nicergoline and its metabolites, decomposition products and impurities in animals. Shintomi K; Yoshimoto K; Ogawa Y; Itakura T; Ikezawa K; Narita H; Ishizuka T; Yamaguchi I; Yamada K J Pharmacobiodyn; 1987 Jan; 10(1):35-48. PubMed ID: 3585694 [TBL] [Abstract][Full Text] [Related]
4. In vitro and in vivo receptor binding and effects on monoamine turnover in rat brain regions of the novel antipsychotics risperidone and ocaperidone. Leysen JE; Janssen PM; Gommeren W; Wynants J; Pauwels PJ; Janssen PA Mol Pharmacol; 1992 Mar; 41(3):494-508. PubMed ID: 1372084 [TBL] [Abstract][Full Text] [Related]
5. [Influence of nicergoline on the cerebral blood flow and alpha-sympatholytical properties (author's transl)]. Lievre M; Ollagnier M; Faucon G Arzneimittelforschung; 1979; 29(8a):1227-31. PubMed ID: 44198 [TBL] [Abstract][Full Text] [Related]
6. Antioxidant properties of MDL and MMDL, two nicergoline metabolites, during chronic administration of haloperidol. Vairetti M; Battaglia A; Carfagna N; Luigi Canonico P; Bertè F; Richelmi P Eur J Pharmacol; 2002 Oct; 453(1):69-73. PubMed ID: 12393061 [TBL] [Abstract][Full Text] [Related]
7. [Metabolic and neurochemical effects of nicergoline on the central nervous system. A review of the experimental studies (author's transl)]. Moretti A Arzneimittelforschung; 1979; 29(8a):1213-23. PubMed ID: 395953 [TBL] [Abstract][Full Text] [Related]
8. Enzyme immunoassay of two nicergoline metabolites, 10 alpha-methoxy-9, 10-dihydrolysergol (MDL) and 1-methyl-10 alpha-methoxy-9, 10-dihydrolysergol (MMDL). Chen P; Tian Z; Digenis GA; Tai HH Res Commun Mol Pathol Pharmacol; 1996 Jun; 92(3):315-28. PubMed ID: 8827829 [TBL] [Abstract][Full Text] [Related]
9. [A review of pharmacological studies on nicergoline]. Moretti A; Arcari G; Pegrassi L Arzneimittelforschung; 1979; 29(8a):1223-7. PubMed ID: 44197 [TBL] [Abstract][Full Text] [Related]
10. Effects of chronic administration of mergocryptine on changes in neurotransmitter levels in the ischemic gerbil brain. Ogawa N; Haba K; Asanuma M; Kawata M; Mori A Arch Int Pharmacodyn Ther; 1990; 308():21-31. PubMed ID: 1983063 [TBL] [Abstract][Full Text] [Related]
11. [The effects of nicergoline on the heart rate in the normotensive or spontaneously hypertensive rat. Possible participation of central alpha-1 receptors]. Huchet AM; Schmitt H J Pharmacol; 1986; 17(1):53-9. PubMed ID: 3012204 [TBL] [Abstract][Full Text] [Related]
12. Effects of the ergot alkaloid elymoclavine on the level and turnover of biogenic monoamines in the rat brain. Petkov VD; Konstantinova E Arch Int Pharmacodyn Ther; 1986 May; 281(1):22-34. PubMed ID: 2428322 [TBL] [Abstract][Full Text] [Related]
13. [Effects of nicergoline on cerebral blood flow (author's transl)]. Iliff LD; Du Boulay GH; Marshall J; Ross Russell RW; Symon L Arzneimittelforschung; 1979; 29(8a):1277-8. PubMed ID: 540071 [TBL] [Abstract][Full Text] [Related]
14. [Nicergoline and platelet aggregation. A review of experimental and clinical studies (author's transl)]. Praga C; Tantalo V; Marangoni R Arzneimittelforschung; 1979; 29(8a):1270-6. PubMed ID: 540070 [TBL] [Abstract][Full Text] [Related]
15. Influence of supidimide on brain neurotransmitter systems of rats and mice. Hennies HH; Günzler WA; Flohé L Arzneimittelforschung; 1984; 34(11):1471-80. PubMed ID: 6084511 [TBL] [Abstract][Full Text] [Related]
16. CI-943, a potential antipsychotic agent. II. Neurochemical effects. Pugsley TA; Coughenour LL; Myers SL; Shih YH; Courtland GG; Berghoff W; Stewart SF J Pharmacol Exp Ther; 1989 Oct; 251(1):113-22. PubMed ID: 2571713 [TBL] [Abstract][Full Text] [Related]
17. Specific binding of 3H-nicergoline in rat brain: comparison with the selective alpha 1-antagonist 3H-prazosin. Diop L; Dausse JP J Pharmacol; 1986; 17(1):65-74. PubMed ID: 3713200 [TBL] [Abstract][Full Text] [Related]
18. Effects of chronic delta-9-tetrahydrocannabinol (THC) administration on neurotransmitter concentrations and receptor binding in the rat brain. Ali SF; Newport GD; Scallet AC; Gee KW; Paule MG; Brown RM; Slikker W Neurotoxicology; 1989; 10(3):491-500. PubMed ID: 2576303 [TBL] [Abstract][Full Text] [Related]
19. [Quantitative EEG examinations on the vigilance stabilizing effect of nicergoline / Results of a double blind study with gerontopsychiatric patients (author's transl)]. Bente D; Glatthaar G; Ulrich G; Lewinsky M Arzneimittelforschung; 1979; 29(11):1804-8. PubMed ID: 543890 [TBL] [Abstract][Full Text] [Related]
20. Myometrial responses in situ to nicergoline, acebutolol, phentolamine and noradrenaline of the rat in proestrus. Acritopoulou-Fourcroy S; Clabaut M; Schrub JC Eur J Pharmacol; 1984 Dec; 107(1):59-64. PubMed ID: 6543175 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]